R Squared Ltd Purchases New Shares in Sanofi $SNY

R Squared Ltd acquired a new stake in Sanofi (NASDAQ:SNY) in the 2nd quarter, Holdings Channel.com reports. The fund acquired 9,010 shares of the company’s stock, valued at approximately $435,000.

A number of other institutional investors have also recently modified their holdings of SNY. Ameritas Advisory Services LLC bought a new stake in shares of Sanofi during the 2nd quarter valued at $28,000. Accent Capital Management LLC bought a new stake in shares of Sanofi during the 1st quarter valued at $29,000. Eastern Bank lifted its position in shares of Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after acquiring an additional 300 shares during the period. Banque Transatlantique SA bought a new stake in shares of Sanofi during the 1st quarter valued at $33,000. Finally, Golden State Wealth Management LLC lifted its position in shares of Sanofi by 619.3% during the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock valued at $35,000 after acquiring an additional 545 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Sanofi Price Performance

Shares of SNY stock opened at $51.64 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12. The company has a market cap of $126.80 billion, a P/E ratio of 12.41, a P/E/G ratio of 1.20 and a beta of 0.51. The business has a fifty day simple moving average of $48.65 and a 200 day simple moving average of $49.55.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. During the same quarter in the prior year, the company earned $1.73 earnings per share. Sanofi’s quarterly revenue was down 7.0% compared to the same quarter last year. On average, sell-side analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Barclays reiterated an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. Finally, Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.